Monday, August 31, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Aug 28, 2026
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
background ▾
- •Vivace Therapeutics appointed new CEO Craig Gibbs and CBSO Ellen Lubman ahead of advancing VT3989 into phase 3 registration for mesothelioma, with the candidate holding FDA Fast Track and Orphan Drug designations
Vivace TherapeuticsMirai BioRhythm PharmaceuticalsVT3989Imcivree
→ Read original articlePolicy•Endpoints News•Aug 28, 2026
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
background ▾
- •Mounjaro receives FDA approval for cardiovascular risk reduction, a major label expansion that positions tirzepatide as a multi-indication blockbuster with potential to capture a much larger patient population beyond diabetes and weight management
- •This approval validates the cardiovascular benefits of dual GIP/GLP-1 receptor agonism and may accelerate adoption across cardiology and primary care settings, intensifying competition with single GLP-1 agents
- •Monitor market penetration in the cardiovascular indication, competitor responses from Novo Nordisk and others, and potential for further label expansions or combination therapies
Eli LillyTevaMounjarotirzepatide
→ Read original articlePolicy•Fierce Biotech•Aug 31, 2026
China in Global Clinical Development: Why Early Inclusion Matters
background ▾
- •China's shift from ICH observer to ICH member (2017) and subsequent NMPA regulatory reforms (implied 60-day IND pathway, 30-day accelerated review for innovative therapies) have fundamentally enabled early-stage parallel enrollment strategies and eliminated the need for costly standalone bridging trials
- •Sponsors integrating China into global development strategies from day one capture significant value through trial speed, cost efficiency, and access to ~5 million annual cancer cases and large patient pools in cardiometabolic and immunology areas
- •China-generated data now carries elevated global regulatory confidence due to investigator MRCT maturity, ICH E17 adoption, and improved infrastructure; sponsors must align statistical plans and endpoints prospectively to fully leverage Chinese cohorts in regulatory submissions
Syneos Health
→ Read original articlePolicy•STAT News•Aug 31, 2026
Opinion: The most shocking thing about the latest statistics on CTE in football is that we find them so shocking
background ▾
- •This is an opinion piece, not pharmaceutical news or clinical trial reporting—it addresses sports policy and public health history rather than drug development, regulatory action, or market access decisions
Policy•KFF•Aug 28, 2026
KFF Survey Methodology & Data Collection Standards
background ▾
Market Access
Market Access•Fierce Biotech•Aug 28, 2026
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
background ▾
- •Teva's $57.5M–$67.5M stalking horse bid provides a floor valuation for BioXcel's neuroscience assets, with regulatory milestones tied to BXCL501's FDA approval decision expected by November 14, 2024
- •BXCL501 approval by the November deadline triggers the full $67.5M milestone; approval between November and February yields $55M; post-February approval shifts to smaller regulatory milestones plus sales-based payments
- •Watch for competing bids in the bankruptcy auction and the FDA's PDUFA decision on BXCL501, which will materially alter the deal economics and Teva's final acquisition cost
BioXcel TherapeuticsTeva PharmaceuticalsBXCL501BXCL701
→ Read original articleMarket Access•Endpoints News•Aug 28, 2026
Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance
background ▾
- •Roche commits $1B+ to DualityBio's ADC platform, signaling major confidence in the company's TOPO1-targeted approach and potentially expanding its oncology pipeline
- •The partnership targets TOPO1 resistance, a clinically relevant problem in cancer treatment that could address a significant unmet medical need
- •Details on specific drug candidates, development timeline, and regulatory pathway remain undisclosed, creating uncertainty around near-term catalysts
RocheGenentechDualityBio
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 28, 2026
AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
background ▾
- •AHB-137 achieved 30% functional cure rate in Phase 2a with no serious drug-related adverse events, providing a clinical foundation for Phase 3 advancement in a large unmet need market (296M patients globally with CHB)
- •GSK's bepirovirsen approval in Japan validates the oligonucleotide approach for CHB and establishes a competitive benchmark; AusperBio's Phase 3 data will determine clinical and commercial differentiation
- •Monitor Phase 3 China trial readout and regulatory submissions in other major markets (US, EU); watch for combination therapy strategies and pipeline progress of AHB-171 siRNA candidate
AusperBio TherapeuticsRA Capital ManagementGSKAHB-137AHB-171bepirovirsen
→ Read original articleClinical Trials•Endpoints News•Aug 30, 2026
#ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closer
background ▾
- •Arrowhead's Redemplo demonstrated superior or comparable safety to Ionis' triglyceride-lowering RNAi program in late-stage trials, a critical differentiator in competitive patient recruitment and label positioning
- •Both Arrowhead and Ionis are advancing RNAi candidates for elevated triglycerides, signaling strong clinical validation of this mechanism but also indicating upcoming competitive intensity in a new indication
- •Watch for regulatory submissions and timelines for both candidates; payer coverage and pricing strategy will be crucial as this new RNAi indication enters the market
Arrowhead PharmaceuticalsIonis PharmaceuticalsRedemplomuvalaplin
→ Read original articleClinical Trials•Fierce Biotech•Aug 28, 2026
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
background ▾
- •BNT122 monotherapy was associated with higher mortality than control in colorectal cancer, leading to trial termination by independent safety review—a rare and serious adverse signal for an mRNA oncology program
- •The failure underscores the critical importance of combining mRNA cancer vaccines with immunotherapy to activate T cells, particularly in immunologically cold tumors with suppressive microenvironments
- •Watch the ongoing BNT122 combination trial with immunotherapy for efficacy and safety signals; also monitor whether this setback affects BioNTech's oncology strategy, partnership commitments, or investor confidence relative to competitors like Moderna
BioNTechGenentechMerckautogene cevumeranBNT122Keytruda
→ Read original articleClinical Trials•Endpoints News•Aug 30, 2026
#ESC26: AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial
background ▾
- •Oral relaxin agonist demonstrated cardiac function improvement in a subset of heart failure patients, though efficacy was not universal
- •Mixed efficacy signals raise questions about patient selection and clinical pathway forward for this mechanism
AstraZenecarelaxin agonist (oral)
→ Read original articleClinical Trials•Endpoints News•Aug 29, 2026
#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure
background ▾
- •Novartis is advancing an anti-IL-6 antibody into Phase 3 for cardiovascular event prevention, directly challenging the viability of the IL-6 pathway after Novo Nordisk's program failure
- •The decision signals either meaningful differentiation in Novartis's asset (mechanism, dosing, patient selection) or confidence in distinct trial design that could succeed where competitors failed
- •Monitor Phase 3 enrollment, interim efficacy signals, and whether regulatory pathways remain open for IL-6 inhibitors in cardiovascular disease given competitive setbacks
NovartisNovo Nordisk
→ Read original article